Lp(a) and UK Biobank
In this project, our goals are (1) to analyse the KIV-2 LPA region in the UK Biobank exome data using novel variant calling strategies in combination with the corresponding Lp(a) concentrations to identify associations between LPA variants and Lp(a) levels as well as clinical endpoints such as cardiovascular, diabetes or chronic kidney disease endpoints, (2) to identify other camouflaged regions similar to LPA using computational approaches and (3) to provide researchers a computational pipeline to analyse other repetitive genome regions.
Principal Investigator (PI)
Publications using UK-Biobank
Di Maio S, Lamina C, Coassin S, Forer L, Würzner R, Schönherr S, Kronenberg F: Lipoprotein(a) and SARS-CoV-2 infections: Susceptibility to infections, ischemic heart disease and thromboembolic events. J. Intern. Med. 291:101-107, 2022. PMID: 34096654
Schachtl-Riess JF, Kheirkhah A, Grüneis R, Di Maio S, Schoenherr S, Streiter G, Losso JL, Paulweber B, Eckardt KU, Köttgen A, Lamina C, Kronenberg F, Coassin S, GCKD Investigators: Frequent LPA KIV-2 variants lower lipoprotein(a) concentrations and protect against coronary artery disease. J. Am. Coll. Cardiol. 78:437-449, 2021. PMID: 34325833
Grüneis R, Lamina C, Di Maio S, Schönherr S, Zoescher P, Forer L, Streiter G, Peters A, Gieger C, Köttgen A, Kronenberg F, Coassin S: The effect of LPA Thr3888Pro on lipoprotein(a) and coronary artery disease is modified by the LPA KIV-2 variant 4925G>A. Atherosclerosis 349:151-159, 2022. PMID: 35534298